Literature DB >> 26859213

68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.

Carl Diedrich Schlenkhoff1, Florian Gaertner, Markus Essler, Stefan Hauser, Hojjat Ahmadzadehfar.   

Abstract

Prostate cancer was diagnosed in a 71-year-old man with an elevated prostate-specific antigen. The CT of the abdomen showed multiple para-aortal lymph nodes, and thus, a Ga anti-prostate-specific membrane antigen (PSMA-11) PET/CT was initiated, which showed, aside from the prostate cancer and multiple iliacal and para-aortal lymph node metastases, an increased tracer uptake in a lymph node left cervical. According to this advanced disease, a palliative therapy with GnRH agonist was initiated. A second PSMA-11 PET/CT was performed 4 months later, which showed a very good response; thus, additional radiation of the pelvis and the draining lymphatic system was performed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26859213     DOI: 10.1097/RLU.0000000000001158

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

1.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Authors:  Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

2.  Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.

Authors:  Chang Liu; Yao Zhu; Hengchuan Su; Xiaoping Xu; Yingjian Zhang; Shaoli Song; Beihe Wang; Dingwei Ye; Silong Hu
Journal:  Cancer Med       Date:  2020-03-12       Impact factor: 4.452

Review 3.  Metal-Based PSMA Radioligands.

Authors:  Eleni Gourni; Gjermund Henriksen
Journal:  Molecules       Date:  2017-03-24       Impact factor: 4.411

4.  Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?

Authors:  Conrad Leitsmann; Paul Thelen; Marianne Schmid; Johannes Meller; Carsten-Oliver Sahlmann; Birgit Meller; Lutz Trojan; Arne Strauss
Journal:  Int Braz J Urol       Date:  2019 May-Jun       Impact factor: 1.541

Review 5.  Clinical perspectives of PSMA PET/MRI for prostate cancer.

Authors:  Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.